← All indications
Leukemia, Megakaryoblastic, Acute
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
Drugs by status
Organizations
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (15)
- Teva
- National Heart, Lung, and Blood Institute (NHLBI)
- Case Western Reserve University
- ECOG-ACRIN Cancer Research Group
- University of Washington
- Johns Hopkins University
- Rutgers University
- Southwest Oncology Group
- Stanford University
- University of South Florida
- Mayo Clinic
- University of Texas at Houston
- State University of New York, Buffalo
- State of Texas
- Yeshiva University
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (2)